IVBTOTCHealthcare · Biotechnology

Innovation1 Biotech Inc.

$0.00+0.00%(+$0.00)

TickerSpark Score

44/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVBT research report →

52-Week Range0% of range

Low $0.00

Current $0.00

High $0.01

Companywww.innovation1bio.com

Innovation1 Biotech Inc. , a drug discovery company, focuses on the development of modified schedule 1 molecules of botanical origin in the United States. Its portfolio includes five proprietary fully synthetic preclinical prodrugs addressing independent clinical indications comprising a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression; a novel cannabinoid and tree bark derived psychedelic for treatment of addiction; and three additional cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation.

CEO: Francis Knuettel
IPO: 2017
Employees: 1
HQ: Somerville, NY, US

Price Chart

-96.00% · this period

Valuation

Market Cap: $4.49K
P/E: -0.00
P/S: 0.00
P/B: -0.00
EV/EBITDA: -0.03
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: 2074.16%
ROIC: 42.71%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-5,988,000 · 85.35%
EPS: $-0.70 · 74.36%
Op Income: $-1,367,000
FCF YoY: 80.19%

Performance & Tape

52W High: $0.01
52W Low: $0.00
50D MA: $0.00
200D MA: $0.00
Beta: 5.83
Avg Volume: 16

Get TickerSpark's AI analysis on IVBT

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime